Sartorius Stedim Biotech: Half-Year Liquidity Statement

Sartorius Stedim Biotech SA released its half-year liquidity contract statement as of December 31, 2025. Under the contract with Kepler Cheuvreux, the liquidity account held 32,966 shares and €6,457,086.94. The company reported 5,079 buy executions and 4,845 sell executions for the semester. The traded buy volume totaled 272,457 shares valued at €51,769,936.60, while sell trades involved 275,047 shares at €52,809,559.69.

In comparison, the prior half-year results from June 30, 2025, showed a liquidity account with 35,556 shares and €5,371,198.80. There were 6,590 buy executions and 6,093 sell executions. The corresponding traded volumes were 341,671 shares for €67,250,964.02 on the buy side and 335,678 shares for €66,313,031.28 on the sell side.

The liquidity contract complies with AMF Decision N°2021-01. Sartorius Stedim Biotech, based in Aubagne, France, is a major partner to the biopharmaceutical industry, facilitating biotech medication production. The company’s shares are listed on Euronext Paris.